Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Obdulia Rabal

Showing results (41-50 of 60) with videos related to

Pageof 6
Sort By:
Chemmedchem|August 2, 2008
Discovery of novel non-cyclam polynitrogenated CXCR4 coreceptor inhibitorsSofia Pettersson, Violeta I Pérez-Nueno, Laia Ros-Blanco, et al.
Journal of Medicinal Chemistry|June 13, 2018
Detailed Exploration around 4-Aminoquinolines Chemical Space to Navigate the Lysine Methyltransferase G9a and DNA Methyltransferase Biological SpacesObdulia Rabal, Juan Antonio Sánchez-Arias, Edurne San José-Enériz, et al.
Bioorganic & Medicinal Chemistry Letters|February 14, 2012
Imidazo[1,2-a]pyrazines as novel PI3K inhibitorsSonia Martínez González, Ana Isabel Hernández, Carmen Varela, et al.
Journal of Medicinal Chemistry|March 4, 2021
Design and Synthesis of Novel Epigenetic Inhibitors Targeting Histone Deacetylases, DNA Methyltransferase 1, and Lysine Methyltransferase G9a with <i>In Vivo</i> Efficacy in Multiple MyelomaObdulia Rabal, Edurne San José-Enériz, Xabier Agirre, et al.
Journal of Medicinal Chemistry|September 9, 2016
Design, Synthesis, and Biological Evaluation of First-in-Class Dual Acting Histone Deacetylases (HDACs) and Phosphodiesterase 5 (PDE5) Inhibitors for the Treatment of Alzheimer's DiseaseObdulia Rabal, Juan A Sánchez-Arias, Mar Cuadrado-Tejedor, et al.
Haematologica|December 2, 2017
Targeting the anion exchanger 2 with specific peptides as a new therapeutic approach in B lymphoid neoplasmsJon Celay, Teresa Lozano, Axel R Concepcion, et al.
ACS Chemical Neuroscience|December 12, 2018
Discovery of in Vivo Chemical Probes for Treating Alzheimer's Disease: Dual Phosphodiesterase 5 (PDE5) and Class I Histone Deacetylase Selective InhibitorsObdulia Rabal, Juan A Sánchez-Arias, Mar Cuadrado-Tejedor, et al.
European Journal of Medicinal Chemistry|March 18, 2018
Design, synthesis, biological evaluation and in vivo testing of dual phosphodiesterase 5 (PDE5) and histone deacetylase 6 (HDAC6)-selective inhibitors for the treatment of Alzheimer's diseaseObdulia Rabal, Juan A Sánchez-Arias, Mar Cuadrado-Tejedor, et al.
The Journal of Biological Chemistry|August 20, 2009
Chemical interrogation of FOXO3a nuclear translocation identifies potent and selective inhibitors of phosphoinositide 3-kinasesWolfgang Link, Julen Oyarzabal, Beatriz G Serelde, et al.
ACS Chemical Neuroscience|August 24, 2019
Multitarget Approach for the Treatment of Alzheimer's Disease: Inhibition of Phosphodiesterase 9 (PDE9) and Histone Deacetylases (HDACs) Covering Diverse Selectivity ProfilesObdulia Rabal, Juan A Sánchez-Arias, Mar Cuadrado-Tejedor, et al.
Pageof 6

Showing results (41-50 of 60) with videos related to

Sort By:
Pageof 6
Chemmedchem|August 2, 2008
Discovery of novel non-cyclam polynitrogenated CXCR4 coreceptor inhibitorsSofia Pettersson, Violeta I Pérez-Nueno, Laia Ros-Blanco, et al.
Journal of Medicinal Chemistry|June 13, 2018
Detailed Exploration around 4-Aminoquinolines Chemical Space to Navigate the Lysine Methyltransferase G9a and DNA Methyltransferase Biological SpacesObdulia Rabal, Juan Antonio Sánchez-Arias, Edurne San José-Enériz, et al.
Bioorganic & Medicinal Chemistry Letters|February 14, 2012
Imidazo[1,2-a]pyrazines as novel PI3K inhibitorsSonia Martínez González, Ana Isabel Hernández, Carmen Varela, et al.
Journal of Medicinal Chemistry|March 4, 2021
Design and Synthesis of Novel Epigenetic Inhibitors Targeting Histone Deacetylases, DNA Methyltransferase 1, and Lysine Methyltransferase G9a with <i>In Vivo</i> Efficacy in Multiple MyelomaObdulia Rabal, Edurne San José-Enériz, Xabier Agirre, et al.
Journal of Medicinal Chemistry|September 9, 2016
Design, Synthesis, and Biological Evaluation of First-in-Class Dual Acting Histone Deacetylases (HDACs) and Phosphodiesterase 5 (PDE5) Inhibitors for the Treatment of Alzheimer's DiseaseObdulia Rabal, Juan A Sánchez-Arias, Mar Cuadrado-Tejedor, et al.
Haematologica|December 2, 2017
Targeting the anion exchanger 2 with specific peptides as a new therapeutic approach in B lymphoid neoplasmsJon Celay, Teresa Lozano, Axel R Concepcion, et al.
ACS Chemical Neuroscience|December 12, 2018
Discovery of in Vivo Chemical Probes for Treating Alzheimer's Disease: Dual Phosphodiesterase 5 (PDE5) and Class I Histone Deacetylase Selective InhibitorsObdulia Rabal, Juan A Sánchez-Arias, Mar Cuadrado-Tejedor, et al.
European Journal of Medicinal Chemistry|March 18, 2018
Design, synthesis, biological evaluation and in vivo testing of dual phosphodiesterase 5 (PDE5) and histone deacetylase 6 (HDAC6)-selective inhibitors for the treatment of Alzheimer's diseaseObdulia Rabal, Juan A Sánchez-Arias, Mar Cuadrado-Tejedor, et al.
The Journal of Biological Chemistry|August 20, 2009
Chemical interrogation of FOXO3a nuclear translocation identifies potent and selective inhibitors of phosphoinositide 3-kinasesWolfgang Link, Julen Oyarzabal, Beatriz G Serelde, et al.
ACS Chemical Neuroscience|August 24, 2019
Multitarget Approach for the Treatment of Alzheimer's Disease: Inhibition of Phosphodiesterase 9 (PDE9) and Histone Deacetylases (HDACs) Covering Diverse Selectivity ProfilesObdulia Rabal, Juan A Sánchez-Arias, Mar Cuadrado-Tejedor, et al.
Pageof 6